SCHEMBL25213301

SCHEMBL25213301

O=C(CBr)c1ccccc1C1CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 4/20 0.49
GSK3B P49841 3/20 0.44
CYP2D6 P10635 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
KCNH2 Q12809 1/20 0.39
HPGDS O60760 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.37
NPC1 O15118 1/20 0.36
HCRTR1 O43613 4/20 0.36
HCRTR2 O43614 4/20 0.36
HSD17B10 Q99714 1/20 0.36
PIN1 Q13526 1/20 0.35
TAS1R3 Q7RTX0 2/20 0.35
TAS1R1 Q7RTX1 2/20 0.35
TAS1R2 Q8TE23 2/20 0.35
OPRL1 P41146 1/20 0.35
ASPH Q12797 1/20 0.35
KDM8 Q8N371 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19566113 0.81 HCRTR1 (0.41) PTGDR2HCRTR1HCRTR2TAS1R3TAS1R1
SCHEMBL25674678 0.81 OPRL1 (0.37) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL25211506 0.80 OPRL1 (0.36) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL28793398 0.79 NPC1 (0.39) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL7357951 0.78 ALDH1A1 (0.41) PTGDR2NPC1HSD17B10PIN1TAS1R3
SCHEMBL23064608 0.77 SLC25A5 (0.39) SLC6A2SLC6A4SLC6A3HCRTR1HCRTR2
SCHEMBL23064673 0.77 OPRL1 (0.38) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL9409754 0.77 PTPN1 (0.65) PTPN1GSK3BHPGDS
SCHEMBL4443007 0.76 SLC6A2 (0.40) CYP2D6SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4109572 0.76 ALDH1A1 (0.54) CYP2D6ASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2025-01-30 US disclosed
EP-4441044-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2024-10-09 EP disclosed
CN-118302422-A Substituted N-cyanopyrrolidines having activity as USP30 inhibitors 特殊治疗有限公司 2024-07-05 CN disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 WO disclosed
WO-2023099561-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2023-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034122-A1 SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP47, USP1 PTPN1 1872/4885GSK3B 4088/4885CYP2D6 3514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.